Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company focused on rare diseases, with news flow centered on its clinical programs, scientific publications, and corporate developments. The company’s updates frequently highlight progress with its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), and its proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform.
Investors following QNCX news can expect regular announcements on the pivotal Phase 3 NEAT clinical trial of eDSP in Ataxia-Telangiectasia (A-T), including milestones such as completion of enrollment, last patient last visit, safety reviews by an independent data and safety monitoring board, and plans for topline data. Quince also issues press releases on related open label extension studies, pediatric investigational plans, and preparation for potential regulatory submissions.
Beyond trial status, Quince’s news includes peer-reviewed publications and conference presentations. Recent communications have described early-stage clinical studies of eDSP in pulmonary and inflammatory bowel disorders, population pharmacokinetic modeling in A-T, and analyses of patient-reported walking capacity in children with A-T. These items provide scientific context for the company’s approach to erythrocyte-based corticosteroid delivery.
Corporate and financial updates are another key component of QNCX coverage. The company reports quarterly financial results, financing transactions, amendments to its European Investment Bank credit facility, and strategic relationships such as its agreement with Option Care Health to support potential commercial launch of eDSP in the United States. Quince also announces participation in healthcare conferences, investor days, and rare disease summits, where management discusses development plans, regulatory strategy, and potential pipeline expansion.
This news page aggregates these clinical, scientific, regulatory, and corporate disclosures so that readers tracking Quince Therapeutics and QNCX stock can review the company’s latest rare disease developments in one place.
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotech company focusing on rare disease treatments through patient biology, has announced its upcoming participation in the Citizens Life Sciences Conference.
The company's leadership, represented by Dr. Dirk Thye, who serves as both CEO and Chief Medical Officer, will deliver a presentation at the conference in New York City on May 7, 2025, at 3:30 p.m. Eastern Time.
Investors and interested parties can access the presentation through a live webcast available on the Events page of Quince's Investor Relations website at ir.quincetx.com. A recording of the presentation will be made available shortly after the live event concludes.
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare disease treatments through patient biology, has announced its upcoming participation in the Jones Healthcare and Technology Innovation Conference.
The company's CEO and CMO, Dr. Dirk Thye, will deliver a presentation on Wednesday, April 9, 2025. Investors and interested parties can access a replay of the presentation through the Events section of Quince's Investor Relations website at ir.quincetx.com.
Quince Therapeutics (NASDAQ: QNCX) reported key progress in its Phase 3 NEAT clinical trial, which has exceeded 50% enrollment with 61 participants randomized. The trial evaluates eDSP for treating Ataxia-Telangiectasia (A-T), with topline results expected in Q4 2025.
The company reported financial results for FY2024:
- Cash position: $40.8 million, expected to fund operations through Phase 3 results into 2026
- R&D expenses: $18.6 million
- G&A expenses: $17.6 million
- Net loss: $56.8 million ($1.31 per share)
Notable developments include FDA Fast Track designation for eDSP, publication of trial results in The Lancet Neurology, and a U.S. patent extension to 2036. The company plans to initiate a Phase 2 trial for Duchenne muscular dystrophy in 2025.
Quince Therapeutics (NASDAQ: QNCX) announced significant progress in its Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T), with enrollment nearing 50%. The company has enrolled 46 participants to date, including 40 in the primary analysis population of six to nine-year-olds, with plans to enroll approximately 86 patients in this age group and 20 patients aged 10 or older.
The NEAT trial is being conducted under a Special Protocol Assessment agreement with the FDA, evaluating EryDex (dexamethasone sodium phosphate encapsulated in autologous red blood cells) for A-T treatment. The company expects to complete enrollment in Q2 2025 and report topline results in Q4 2025.
An open-label extension has been initiated with 17 participants enrolled across the U.S., U.K., and European Union. Pending positive results, Quince plans to submit a New Drug Application to the FDA and a Marketing Authorization Application to the EMA in 2026.
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare disease treatments, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's CEO and CMO, Dr. Dirk Thye, will engage in a fireside chat during this virtual event on Wednesday, February 12, 2025, at 2:00 p.m. Eastern Time.
Investors and interested parties can access the live webcast through the Events page in the News & Events section of Quince's Investor Relations website at ir.quincetx.com. A recording of the presentation will be made available shortly after the live event concludes.
Quince Therapeutics (NASDAQ: QNCX) has received a Notice of Allowance from the USPTO for a patent application covering their method of treating Ataxia-Telangiectasia (A-T) using the EryDex process. The patent, extending to 2036, covers the preparation of erythrocytes loaded with pharmaceutical substances.
The new patent application supplements existing U.S. Patent No. 10,849,858 and features broader claims than the parent patent. Once issued, the patent will be listable in the FDA's Orange Book, requiring generic applicants to certify against Quince's patent, providing notice of future generic applications and stay provisions under the Hatch-Waxman Act.
This protection complements the market exclusivity provided by Orphan Drug Designation in both the U.S. and Europe. The company plans to pursue similar claims with the European Patent Office.
Quince Therapeutics (Nasdaq: QNCX) has announced an upcoming investor webinar focused on Ataxia-Telangiectasia (A-T), scheduled for February 7, 2025, at 10:00 a.m. Eastern Time. The webinar will feature Dr. Mary Kay Koenig, a leading A-T expert and board-certified child neurologist, who will present on A-T natural history, current treatments, competitive landscape, and Quince's Phase 3 EryDex clinical trial.
Dr. Dirk Thye, Quince's CEO and CMO, will provide a corporate overview and update on the ongoing Phase 3 NEAT clinical trial enrollment. Dr. Koenig, currently serving as Professor and Associate Vice-Chair for Clinical Research at McGovern Medical School, brings extensive expertise in neurodegenerative disorders and holds multiple leadership positions, including Director at the Center for Treatment of Pediatric Neurodegenerative Disease.
Quince Therapeutics (NASDAQ: QNCX) announced the publication of safety data in Frontiers in Neurology regarding EryDex treatment in pediatric patients with Ataxia-Telangiectasia (A-T). The data comes from patients treated for a minimum of 24 months in Phase 3 clinical trials.
EryDex, which encapsulates dexamethasone sodium phosphate in patients' own red blood cells, demonstrated favorable safety profiles without the typical chronic side effects associated with standard corticosteroid treatment. The company has administered over 6,000 monthly doses to nearly 400 patients over 10+ years.
The most common treatment-related side effect was temporary infusion-related pruritus. The company is currently conducting the pivotal Phase 3 NEAT trial under a Special Protocol Assessment agreement with the FDA, with topline results expected in Q4 2025. Quince plans to submit New Drug Application to FDA and Marketing Authorization Application to EMA in 2026, pending positive results.
Quince Therapeutics (Nasdaq: QNCX) has appointed Dr. William Whitehouse to its Scientific Advisory Board (SAB). Dr. Whitehouse, an Honorary Clinical Associate Professor at the University of Nottingham and retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, brings extensive expertise in rare pediatric neurodegenerative diseases, particularly Ataxia-Telangiectasia (A-T). He joins seven founding SAB members who are experts in various medical fields.
Dr. Mauro Magnani, Chair of Quince's SAB, highlighted Dr. Whitehouse's valuable contributions to advancing Quince's lead asset, EryDex, aimed at treating A-T. Dr. Whitehouse expressed enthusiasm for collaborating with Quince's team to support EryDex's development, which has the potential to be a first-to-market treatment for A-T.
Dr. Whitehouse has a distinguished academic and clinical background, with significant contributions to A-T research and care. His appointment is expected to bolster Quince's efforts in treating rare diseases, with a pivotal Phase 3 clinical trial for EryDex currently underway. Quince's SAB will also aid in expanding the company's pipeline to include other rare disease indications.